NCT00349349View on ClinicalTrials.gov

HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab

PHASE2CompletedINTERVENTIONAL
Enrollment

223

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

May 31, 2008

Study Completion Date

June 30, 2012

Conditions
Leukaemia, Lymphocytic, Chronic
Interventions
DRUG

ofatumumab

Intravenous infusion

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00349349 - HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab | Biotech Hunter | Biotech Hunter